Thermo Fisher Scientific Introduces Hematology-Oncology Portfolio
The Oncomine Myeloid Assay GX is the first in a series of clinical research assays available from the new hematology-oncology portfolio.
Read MorePosted by Melanie Hamilton-Basich | Aug 21, 2020 | Cancer, Molecular Diagnostics |
The Oncomine Myeloid Assay GX is the first in a series of clinical research assays available from the new hematology-oncology portfolio.
Read MorePosted by | May 4, 2020 | Breast, Cancer, Cervical (HPV), Leukemia, Lung Cancer, Lymphoma, Melanoma, Molecular Diagnostics, Pancreatic, Prostate, Unknown Origin & Other Cancer Types |
The blood test followed by PET-CT imaging was 99.6% specific for cancer.
Read MorePosted by | Apr 27, 2020 | Biochemicals & Chemical Reagents, Cancer, Melanoma, Tissue Processing |
The launch focuses on several immunooncology markers that are critical for early-stage cancer drug development and patient treatment.
Read MorePosted by | Apr 21, 2020 | Cancer, Cardiovascular, Computing Systems, Gastrointestinal Infections, Information Technology, Leukemia, Middleware & Software, Molecular Diagnostics |
A noninvasive blood test may provide a ‘crystal ball’ for early detection of infections, leading to increased cure rates among pediatric leukemia patients.
Read MorePosted by | Apr 21, 2020 | Breast, Cancer, Cervical (HPV), Leukemia, Lung Cancer, Lymphoma, Melanoma, Molecular Diagnostics, Pancreatic, Prostate, Unknown Origin & Other Cancer Types |
The Pathfinder study will enroll 6,200 participants to evaluate Grail’s investigational multicancer early detection test in clinical practice.
Read More